title: Abrogation of chronic rejection in a murine model of aortic allotransplantation by prior induction of donor-specific tolerance.
abstract: Aortic allotransplantation in mice has been well established as a model of choice to study the evolvement of chronic rejection, the etiopathology of which is believed to be that of immune origin. This has prompted the postulation that prior induction of donor-specific tolerance would attenuate or abrogate the underlying events that culminate in posttransplant arteriosclerosis. To study the effects of donor-specific tolerance on chronic rejection, we performed orthotopic liver transplantation without immunosuppression in mice 30 days before aortic allotransplantation across C57Bl/ 10J (H2b)-->C3H (H2k) strain combinations (group III). Aortic allografting in syngeneic (group I; C3H-->C3H) and allogeneic (group II, C57Bl/10J-->C3H) animals served as controls. No morphological changes were evidenced in the transplanted aortas in group I animals. Contrarily, aortic allografts in group II animals underwent a self-limiting acute cellular rejection, which resolved completely and was succeeded by day 30 after transplantation by histopathological changes pathognomonic of chronic rejection. There was evidence for diffuse myointimal thickening, progressive concentric luminal narrowing, and patchy destruction of internal elastic membranes resulting in massive vascular obliteration by day 120 after transplantation. It was of interest that no arteriosclerotic changes were observed for the duration of follow-up (up to 120 days after transplantation) in transplanted aortas (liver donor-type) harvested from animals in group III. However, vasculopathy was prominent in third-party aortic grafts transplanted into tolerant recipients. Taken together, these data suggest that prior induction of tolerance abrogates the development of chronic rejection; this protection seems to be donor specific.
authors.affiliation: Thomas E. Starzl Transplantation Institute and the Department of Surgery, University of Pittsburgh Medical Center, Pennsylvania 15261, USA.
authors.forename: V
authors.initials: V
authors.lastname: Subbotin
authors.forename: H
authors.initials: H
authors.lastname: Sun
authors.forename: A
authors.initials: A
authors.lastname: Aitouche
authors.forename: L A
authors.initials: LA
authors.lastname: Valdivia
authors.forename: J J
authors.initials: JJ
authors.lastname: Fung
authors.forename: T E
authors.initials: TE
authors.lastname: Starzl
authors.forename: A S
authors.initials: AS
authors.lastname: Rao
mesh_terms: D000818:Animals; D001013:Aorta, Thoracic / Q000637:transplantation*; D006084:Graft Rejection / Q000517:prevention & control*; D007108:Immune Tolerance / Q000502:physiology*; D016031:Liver Transplantation / Q000276:immunology; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D008809:Mice, Inbred C3H; D008810:Mice, Inbred C57BL; D016377:Organ Transplantation / Q000473:pathology / Q000502:physiology; D013997:Time Factors; D019172:Transplantation Conditioning